|Bid||209.00 x 800|
|Ask||0.00 x 800|
|Day's Range||208.81 - 214.48|
|52 Week Range||150.37 - 236.62|
|Beta (3Y Monthly)||0.68|
|PE Ratio (TTM)||12.08|
|Earnings Date||Jun 27, 2019 - Jul 1, 2019|
|Forward Dividend & Yield||2.96 (1.69%)|
|1y Target Est||219.86|
CNBC's "Power Lunch" hosts the 2019 Stock Draft. Former NFL defensive end Jarvis Green, entrepreneur and author Bethenny Franke and former NFL player Nick Lowery make their first round picks. This year's participants include former NFL defensive end Jarvis Green, entrepreneur and author Bethenny Frankel and former NFL player Nick Lowery, Seymour Asset Management founder Tim Seymour, O'Shares ETFs chairman Kevin O'Leary, Wall Street mentalist Oz Pearlman, and the Beardstown Ladies.
Famed value investor Bill Nygren, Oakmark portfolio manager, joins 'Fast Money Halftime Report' to discuss General Electric, bank stocks, market sentiment and why he's buying Constellation Brands.
Canopy Growth's Bruce Linton appeared on Yahoo Finance, talking about the success of its product and what he would consider a "worst case scenario" for the company. Emily Paxhia, Poseidon Asset Management Managing Partner, joins Seana Smith on 'The Ticker' to discuss Canopy Growth's recent Acreage Holdings deal.
The beverage giant's $4 billion bet on Canopy Growth is only the first step in building a leading global alcohol and cannabis enterprise.
Canopy Growth (NYSE:CGC) has surged higher on a deal that will position the firm to buy U.S.-based Acreage Holdings (OTCMKTS:ACRGF). The agreement, contingent on the U.S. legalizing marijuana at the federal level, would position Canopy as the leading cannabis company in the U.S. Unfortunately for investors, Canopy Growth is not CGC stock.Source: Shutterstock With CGC trading at bubble-like multiples and the challenges facing marijuana stocks and the market in general, I would not buy Canopy Growth stock on the proposed Acreage deal. The Acreage Deal Is a Visionary Move for Canopy GrowthFrom a business standpoint, I love this deal with Acreage Holdings. Now that Canada has fully legalized weed, the focus has shifted to the U.S., a market with nearly nine times the population. Yes, marijuana remains illegal on the federal level. However, the deal only occurs if the U.S. legalizes cannabis nationwide.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 5 Hot Dividend Stocks to Buy as the Weather Heats Up Moreover, it looks more like pot's legal status in the U.S. has become only a question of time. The Jeff Sessions tenure as Attorney General was likely the last hurrah of the pot prohibitionists. Former Republican House Speaker John Boehner once opposed weed. Now he has become a leading advocate of legalization. Even deep-red states have moved to loosen restrictions.Once weed becomes legal, the deal probably leaves Canopy in a better position to benefit than any of its peers. As a result, CGC stock has risen by nearly 19% in ten days.In one sense, I find this surge understandable. Due to investments by Constellation Brands (NYSE:STZ) and now, the Acreage deal, I see CGC as the stock to own within this sector. However, a bigger question hinges on whether investors should own stocks in this sector at all. CGC Stock Faces Unappreciated DangersMarijuana stocks have returned to the high multiples seen right before Canada officially legalized. While I see CGC stock and many of its peers as long-term winners, traders need to exercise caution. CGC trades at more than 96 times sales and over 357 times forward earnings. For now, such multiples have become the norm in this industry. Still, investors need to remain wary of these valuations for two reasons.First, the current bull market has reached its 11th year. This does not necessarily mean that stocks will stop rising soon. However, it increases the danger of such a downturn. Investors tend not to tolerate high valuations under such conditions.Moreover, we should not forget that legalization in Canada set off a "sell the news" type of reaction across the sector. As a result, CGC stock fell by over 57% between October 16th and December 24th. Thanks to pre-legalization anticipation switching to the U.S., Canopy Growth stock recovered most of that lost value.Still, after pot achieves legal status in the U.S., CGC stock will more than likely compare to Altria (NYSE:MO) or that of its largest investor, Constellation Brands. Both MO and STZ have long supported relatively low P/E ratios and high dividends. Such stocks usually benefit from healthy revenues, but they generate little investor excitement.Analysts predict 80.4% earnings growth for CGC next year. Despite that rate of increase, it will take more than another 57% drop to make Canopy look like an Altria. I would recommend CGC stock if it became such an equity. However, at current levels, I see more danger than upside. The Bottom Line on CGC StockBoth valuation and the likely late-stage status of the current bull market make CGC stock one to avoid despite the Acreage Holdings deal. Assuming pot achieves full legal status in the U.S., the Acreage deal will probably position Canopy Growth ahead of its U.S. and Canadian peers.However, the problem lies with CGC stock itself -- and all marijuana stocks. With multiples already in the stratosphere, it will need ever-higher levels of euphoria to surge higher. In the 11th year of an overall bull market, that order only becomes taller. Consequently, the Acreage-driven surge looks more like a selling opportunity than a buy signal. * 7 Dividend Stocks That Could Double Over the Next Five Years If and when the U.S. legalizes, Canopy Growth stock will likely become one that supports a low P/E and pays a generous dividend. Until CGC looks ready to become that type of stock, traders face more potential risk than reward.As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dividend Stocks That Could Double Over the Next Five Years * 6 S&P 500 Stocks Ready to Break Out * 5 Mining ETFs to Dig Into Compare Brokers The post Acreage Deal Helps Canopy Growth More Than It Helps CGC Stock appeared first on InvestorPlace.
Constellation Brands Inc is engaged in the beverage industry. The dividend yield of Constellation Brands Inc stocks is 1.43%. Constellation Brands Inc had annual average EBITDA growth of 24.80% over the past ten years.
After looking like they were set to break down, shares of Canopy Growth (NYSE:CGC) have been surging over the past few trading sessions. As such, CGC stock is up almost 20% over the past five days and on the cusp of breakout territory, with higher prices on many bulls' radar.Source: Shutterstock What so suddenly has CGC stock back in investors' good graces? To be fair, the company didn't really do anything to fall out of their good graces. Rather, it was simply the fading momentum of marijuana stocks at the time.However, momentum was restored in Canopy Growth stock once reports began circulating about its intention to purchase Acreage Holdings (OTCMKTS:ACRGF). The deal is for $300 million in cash and swelled to $3.4 billion once Canopy included 0.58 shares for each subordinate voting share of ACRGF.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Digital Ad Stocks That Deserve Your Attention Right Now Investors are viewing the deal favorably as Acreage Holdings has exposure in 20 different U.S. states. In other words, it's Canopy's way of pushing into the U.S. This comes as it focuses on its future and growing its market share. At the end of the day, market share is a very important component to the cannabis industry. That's one reason why Canopy is considered the leader of this group. Trading CGC StockThe charts for CGC stock look a little busy here, but each level is relevant. The recent action has shown a return of momentum to Canopy Growth stock, but also names like Aurora Cannabis (NYSE:ACB) and Cronos Group (NASDAQ:CRON), among others. It's even given a boost to names like Constellation Brands (NYSE:STZ), which has a near-40% stakes in CGC.That momentum has carried CGC stock into a potentially large breakout area over $48. Where can it go? One analyst says Canopy could run to $72, implying about 90% upside from current levels. Can it actually get there?$48 is the first key test. In the last three trading sessions, CGC stock reclaimed its 20-day and 50-day moving averages as well as prior uptrend support (blue line No. 1). It also cleared prior downtrend resistance (blue line No. 2) and key resistance at $48. Now hovering near $48.25, it's important that CGC stock doesn't give up these recent gains.Whether it can burst through its prior highs near $59 and run to $72 is currently unknown. But if it wants any shot at doing even that, it needs to hold over some of these key levels that it just cleared.Here's what to watch: $48 and prior downtrend resistance (blue line No. 2). According to the RSI, CGC stock is not overbought even after its strong rally over the past few days. According to its MACD reading, momentum is returning to the bulls' favor and could have a lot of upside going forward. Ideally we would see a continuation higher or consolidation near current levels, before a pullback to $48 that holds as support.If $48 soon acts as resistance, bulls need to see the backside of prior downtrend resistance act as support. Bottom Line on Canopy Growth StockIf investors feel that there is momentum in cannabis stocks, then CGC stock is certainly one of the top considerations to ride that wave. In the end though, this is a speculative group and investors have to remember that going forward. This isn't some blue chip stock with a reasonable valuation and strong cash flows.Last quarter (Q3, fiscal 2019), the company had $60.8 million in revenue. That's roughly the same total as it did for all of fiscal 2018. Clearly the growth is very impressive, but we're talking about a company that has consensus expectations for $176 million in sales this year vs. a market cap of more than $16 billion.Granted, estimates call for more than $600 million in sales in fiscal 2020 (which starts in one quarter), but this is still a lofty valuation. That's why M&A deals (such as with Constellation) are so important. It puts billions of dollars into Canopy's coffers, allowing it run its operations and make deals like it did for ARCGF. * 10 High-Yielding Dividend Stocks That Won't Wilt It's a speculative group, but Canopy is among the best in the business.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 High-Yielding Dividend Stocks That Won't Wilt * 4 Energy Stocks Soaring as Trump Tightens on Iran * 7 Tech Stocks With Too Much Risk, Not Enough Upside Compare Brokers The post Is Canopy Growth Stock Set to Break Out and Rally 90%? appeared first on InvestorPlace.
The alcoholic-beverage company owns 38% of Canopy Growth, which agreed to buy the U.S. pot seller Acreage Holdings once cannabis becomes legal under U.S. law.
Even in a space with as much excitement as marijuana stocks, Aphria (NYSE:APHA) stood out for having as much drama as a cable TV show. If you're a trader, APHA stock has been a dream lately. The stock rocketed from $8 to $16 in a month last summer. It then lost as much as 75% of its value, plummeting to $4, after a series of short seller reports. Since then, the stock has bounced 150% off the lows to return to the $10 level, before earnings sent it falling once more.Source: Shutterstock After all the excitement, what's next for APHA stock? And have the company's recent moves made it investable again, or is Aphria only appropriate for the most steel-nerved traders? Fallout From the Bearish Short Seller's ReportsA few months ago, short sellers hit APHA stock with heavy fire. Bearish analysts published reports suggested that Aphria's management had engaged in unscrupulous behavior.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe short sellers suggested that Aphria was engaged in all sorts of questionable if not worse activity. The short sellers said that the company had bought phantom assets in Latin America, engaged in various double-dealing and related party transactions, and numerous other red flags.Aphria's board of directors engaged an independent special committee to investigate the accusations. The special committee found some troubling factors, but its results also exonerated the company in various ways. Arguably the most important finding was that the committee confirmed that Aphria's Latin American assets in fact exist and are progressing toward commercial activity. * 7 Tech Stocks With Too Much Risk, Not Enough Upside The committee suggested that Aphria paid near the top end of a reasonable price range for the assets, but that there is a real business there, unlike the short seller's reports which had claimed these transactions were largely imaginary. New Management for APHA StockHowever, Aphria wasn't blameless either. The board disclosed that: "it appears that certain of the non-independent directors of the Company had conflicting interests in the Acquisition that were not fully disclosed to the Board."Probably in conjunction with that, Aphria has seen major management changes. Former Aphria CEO Vic Neufeld has stepped down, as well as Co-founder Cole Cacciavillani. Neufeld in particular was implicating in several of the alleged misdeeds that the short sellers identified.In his place, Aphria has appointed an interim CEO. Irwin Simon is now in charge, at least for the time being. Simon led Hain Celestial (NASDAQ:HAIN) for more than two decades, helping that company take a dominant position in the natural and organic foods space. While it is obviously a weak spot for Aphria not to have a permanent CEO in place yet, Simon seems to have capable hands to manage the company while it recovers from the reputational blows it suffered recently. Aphria Has a Rough Earnings ReportAs William White pointed out, Aphria plummeted on April 15 after an earnings report "with losses per share of 20 Canadian cents. This is a drop from the company's earnings per share of 8 Canadian cents from the same time last year. It was also bad news for APHA stock by missing analysts' losses per share estimate of 4.5 Canadian cents for the quarter."Revenue was up, but overall sales numbers fell. The market was unimpressed, and the stock is now down around 24% since the report.Back in December, new upstart cannabis firm Green Growth Brands (OTCMKTS:GGBXF) bid to acquire Aphria. This was a highly unusual deal for several reasons. Among them, Green Growth brands itself had just gone public as the merger of several other firms. Additionally, Aphria had a significantly larger market cap than Green Growth, making it a rather odd target for a takeover offer.After the earnings tumble, Green Growth stepped away from their takeover attempt. It may be good for Aphria that another element of uncertainty is gone, but it's hardly unequivocal good news overall. APHA Stock VerdictIt's good that Aphria has cleaned house. That was a necessary and important first step in recovering the market's trust in Aphria going forward. But there's still a lot to be uncertain of.Particularly in a market where so many of the big leaders in the space have deals with credible partners, it's easy to take a pass on APHA stock. Cronos (NASDAQ:CRON) has Altria (NYSE:MO) while Canopy Growth (NYSE:CGC) has partnered with Constellation (NYSE:STZ). Meanwhile, Aurora (NYSE:ACB) doesn't have a major partner yet, but its management team hasn't given us any big reasons to doubt its credibility either.The marijuana stock sector is the Wild West right now. Many of the companies out there are going to crash and burn in coming years. Aphria's efforts to clean up their act are appreciated. But in such a risky sector, at least for the time being, it's advisable to stick to more trustworthy leaders in the cannabis space.At the time of this writing, Ian Bezek owned MO stock. You can reach him on Twitter at @irbezek. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Tech Stocks With Too Much Risk, Not Enough Upside * 7 Companies That Are Closing the CEO-Worker Wage Gap * 7 Video Game ETFs That Will Make You a Winner Compare Brokers The post After the Drama, Where Is Aphria Headed Now? appeared first on InvestorPlace.
Ever since the cannabis craze hit Wall Street back in mid-2018, I've been pounding on the table saying that the best marijuana stock to buy in the group is Canopy Growth (NYSE:CGC). The logic is simple: In addition to being the biggest player in the industry, CGC stock has long had one thing that no other cannabis company has -- $4 billion in cash from Constellation Brands (NYSE:STZ).Source: Shutterstock That $4 billion gives Canopy unprecedented visibility into being one of the industry's long-term winners through early, aggressive, and large investments. As such, I have consistently reasoned that CGC stock belongs in every cannabis-related portfolio.This bull thesis got a big boost in mid-April. Canopy struck a deal with major U.S. cannabis operator Acreage to buy that company for $3.4 billion once cannabis is legalized nationwide in the U.S.InvestorPlace - Stock Market News, Stock Advice & Trading TipsFor those who don't follow this industry closely, that's a big deal. Canopy is the star player in the legal Canadian cannabis market. But the Canadian market is peanuts. The big deal here is the U.S. market. Depending on who you ask, that market is about tenfold the size of the Canadian market.Thus, the big question for Canopy and other Canadian pot stocks is whether or not these companies can replicate their success in the U.S. * 7 Strong Buy Stocks the Street Loves Canopy just answered that question in emphatic fashion, and the market is reacting favorably. CGC stock popped roughly 10% on the news.In the big picture, thanks to a $4 billion early investment from Constellation Brands, Canopy has given itself unprecedented visibility into being a long-term cannabis market leader. Right now, following the Acreage deal, that visibility is as strong as ever. Consequently, the long-term bull thesis for CGC is likewise as strong as ever. The Acreage Acquisition Is Big NewsThere's a reason CGC popped 10% in response to the company agreeing to acquire Acreage. In plain English, it positions the company to fully capitalize on the $100 billion U.S. cannabis market from the onset.First, some context. The whole Wall Street cannabis craze has been largely centered around one thing: the nationwide legalization of cannabis in Canada in late 2018. Roughly speaking, that single catalyst turned the big four Canadian pot stocks -- Canopy, Aurora (NYSE:ACB), Tilray (NASDAQ:TLRY) and Cronos (NASDAQ:CRON) -- from relatively unknown companies to Wall Street household names with multi-billion dollar market caps.But, while Canadian market legalization was the catalyst, it wasn't the prize. The prize here is the U.S. market, which most estimates put at a $100 billion opportunity, versus $10 billion in Canada. The consensus thesis is that, with cannabis fully legal throughout Canada and hemp legal throughout the U.S., it's only a matter of time before cannabis is fully legal across the entire U.S. The big question is whether or not Canadian cannabis giants like Canopy will be able to capitalize on the big U.S. opportunity when it comes knocking.Canopy just answered that question. By agreeing to acquire Acreage -- a major U.S. cannabis operator with dozens of dispensaries and cultivation sites across 20 states -- Canopy has positioned itself to capitalize on the $100 billion U.S. cannabis market opportunity from the onset. That is, as soon as cannabis is fully legal across the U.S., Canopy will be everywhere through Acreage -- and ready to dominate the U.S. market like it's dominated the Canadian market.That's a big deal. Indeed, it paves the path for CGC to head materially higher in a long-term window. Canopy Growth Stock Has Long-Term UpsideMy long-term bull thesis on Canopy Growth stock is that, if this company can successfully maintain its leadership position as the cannabis industry goes global and matures, then this is a $100 billion company in the making. With more visibility than ever to U.S. market domination, that long-term bull thesis looks about as good as ever.The details of my analysis behind the $100 billion number can be found here. But the short recap is pretty easy to understand. At scale, given current consumption trends, the recreational cannabis market could one day be as big as the alcoholic beverage and tobacco markets. What's more, if you consider the medical opportunity, then the aggregate global cannabis market will easily one day be as big as, if not bigger than, the alcoholic beverage and tobacco markets.The top dogs in those two industries have $100 billion-plus market caps. Witness Anheuser-Busch (NYSE:BUD) or Altira (NYSE:MO). Thus, it's only reasonable to assume that the top dogs in the global cannabis industry at scale will be $100 billion-plus companies too.Given its early leadership position, huge financial resources, aggressive management team, large growing capacity, and global distribution network, Canopy has all the tools necessary to turn into a top dog in the global cannabis industry in a decade. Now, Canopy also has visibility to be a top dog in the U.S. market. Thus, this company continues to take steps towards securing global leadership.So long as the company remains on that path, CGC stock will remain on an uptrend towards a $100 billion valuation. * 10 Dividend Growth Stocks You Can't Miss Bottom Line on CGC StockThere are a lot of pot stocks out there, but none of them have as much long-term visibility as Canopy Growth. Given this, if you're buying into the cannabis industry with a multi-year horizon, CGC stock is the best pick in the industry, without question.As of this writing, Luke Lango was long CGC and ACB. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Dividend Stocks Perfect for Retirees * 7 Reasons the Stock Market Rally Isn't Over Yet * 10 S&P 500 Stocks to Weather the Earnings Storm Compare Brokers The post This Is Why Canopy Growth Is the Best Pot Stock appeared first on InvestorPlace.
Constellation Brands, Inc. Class A (NYSE:STZ) and Canopy Growth Corp (NYSE:CGC) have announced that they have agreed to make some changes to various warrants and rights. The new agreement to change some of the warrants and rights that influence their partnership is believed to have been influenced by Canopy’s plans to acquire Acreage Holdings Inc […]The post Constellation Brands, Canopy Growth Sign Deal To Revise Warrants appeared first on Market Exclusive.
The annual marijuana day celebration on April 20 led to a crash of delivery websites, including the biggest legal delivery app, Eaze, as companies struggled to keep up with demand.
One of the big themes in the cannabis sector in 2019 has been increased Wall Street coverage. Specifically, Wall Street firms were largely unwilling to cover cannabis stocks in 2018 given the industry's relative newness, rampant investor speculation and lack of fundamental tangibility. But, things have changed for marijuana stocks in 2019. The industry is less new. There's less speculation. The fundamentals have become significantly more tangible. As such, Wall Street firms have more broadly launched coverage on pot stocks in 2019.Source: Shutterstock One big firm that just initiated coverage on pot stocks is Bank of America. Their take? Of the Big Four pot stocks -- Canopy Growth (NYSE:CGC), Aurora Cannabis (NYSE:ACB), Cronos Group (NASDAQ:CRON) and Tilray (NASDAQ:TLRY) -- the only two worth buying right now are Canopy and Aurora.This isn't an isolated viewpoint. According to TipRanks data, 10 analysts cover CGC stock, while eight analysts cover ACB stock. Of those 18 ratings between CGC and ACB, none of them are Sell ratings. Instead, the consensus rating on CGC stock is "Moderate Buy" while on ACB stock, it's "Strong Buy."InvestorPlace - Stock Market News, Stock Advice & Trading TipsMeanwhile, a third of the nine analysts who cover CRON stock have a "Sell" rating on the shares. The consensus rating is a "Hold." Half of the 10 analysts that cover TLRY stock have a "Sell" rating on the name. The consensus rating on TLRY is a "Hold," too.In other words, the broad consensus among Wall Street firms is that when it comes to the cannabis space, investors should buy CGC and ACB, and forget about CRON and TLRY for the time being. I largely agree with consensus Wall Street view. Here's why. Why Buy CGC Stock?The plain answer here is you buy CGC stock because this company has the most visibility today among all pot stocks to one day transform into a long term market leader. * 7 High-Risk Stocks With Big Potential Rewards Canopy has everything you'd want in an early-stage leader in a big-growth market. Sales leadership? They dwarf everyone else in the space when it comes revenues. Growth? They are growing just about as fast as anyone in the space, despite a much bigger base. Production leadership? They sell far more kilograms of cannabis than anyone else, and have among the largest production footprints in the world. Market expansion? They are pushing aggressively into the U.S. hemp market. Confident leadership? CEO Bruce Linton just said that Canopy will generate over C$1 billion ($748 million) in sales over the next 12 months. Celebrity connections? They have ties with Seth Rogen, Snoop Dogg, and Martha Stewart.Above all else, though, Canopy has the financial resources and firepower to sustain and even grow its early lead. A few quarters ago, alcoholic beverage giant Constellation Brands (NYSE:STZ) poured $4 billion into Canopy. The company still has $3 billion of that left on the balance sheet. That's almost double what any of its competitors have in terms of cash on hand.While 2018 saw a blockbuster year (with nearly $14 billion raised) for cannabis investments, 2019 is on pace to blow past that total, according to cannabis research provider New Frontier Data. Click to EnlargeThus, Canopy has far more firepower than anyone else in this space to invest in growth opportunities, expand operations, expand production, acquire smaller players, so on and so forth. As such, the company does reasonably project as a long-term leader in the global cannabis market, and that's why buying CGC stock today makes sense. Why Buy ACB Stock?The plain answer here is you buy ACB stock because this is the cheapest pot stock in the group for reasons that are most likely temporary.On a pure valuation basis, ACB stock is as cheap as it gets in the cannabis space. Across every metric -- trailing sales, forward sales, market cap per kilogram, annualized revenue -- ACB stock is considerably cheaper than its peers. We are talking a 20%+ undervaluation gap. * 7 Stocks to Buy for Spring Season Growth This relative undervaluation has nothing to do with operating fundamentals. Aurora is big, with the second-largest sales base in the market behind Canopy. The company controls about 20% of the Canadian adult-use market. They also have tremendous production capacity (Aurora has 500,000 kilograms per year in funded capacity) and gross profit margins are among some of the healthiest in the business.Instead, the relative undervaluation in ACB stock has to do with balance sheet. Specifically, unlike peers Canopy and Cronos, Aurora hasn't scored a big investment from a consumer staples giant. Thus, the balance sheet isn't overflowing with billions of dollars to help fund growth. Instead, Aurora has just over $100 million in cash on hand.This won't last forever. Aurora is a big and leading company in the rapid growth cannabis space. The stock is also trading at a huge discount to peers. Thus, it truly is only a matter of time before some big consumer staples company pumps a billion bucks in here, or more. When that happens, the relative undervaluation gap will disappear, and ACB stock will rally in a big way. Bottom Line on CGC Stock and ACB StockThe cannabis sector reeks of long-term potential. But, a lot will happen between now, and when the market matures, and that means that investors need to choose wisely when investing in pot stocks this early in the game.Investment translation? Only buy CGC stock and ACB stock. There are very good reasons to own those two pot stocks here and now, and they should rally over the next several quarters.As of this writing, Luke Lango was long CGC and ACB. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Dividend Stocks Perfect for Retirees * 7 Reasons the Stock Market Rally Isn't Over Yet * 10 S&P 500 Stocks to Weather the Earnings Storm Compare Brokers The post Why These Are the Top 2 Pot Stocks to Buy Right Now appeared first on InvestorPlace.
How far off is Constellation Brands, Inc. (NYSE:STZ) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by projecting its future cash flows and then discounting t...
The top beer stocks have a market cap exceeding $2 billion and are trading on leading American stock exchanges. Here are the top beer stocks of 2018.
Constellation Brands is boosting its U.S. beer business while betting that marijuana products will deliver big sales.